{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:13:43Z","timestamp":1791825223723,"version":"4.3.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2013,11,20]],"date-time":"2013-11-20T00:00:00Z","timestamp":1384905600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1007\/s00702-013-1114-x","type":"journal-article","created":{"date-parts":[[2013,11,19]],"date-time":"2013-11-19T04:54:42Z","timestamp":1384836882000},"page":"357-366","source":"Crossref","is-referenced-by-count":20,"title":["Efficacy of levodopa\/carbidopa\/entacapone versus levodopa\/carbidopa in patients with early Parkinson\u2019s disease experiencing mild wearing-off: a randomised, double-blind trial"],"prefix":"10.1007","volume":"121","author":[{"given":"Eduardo","family":"Tolosa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basilio","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurutz","family":"Linazasoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Jos\u00e9","family":"L\u00f3pez-Lozano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Mir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Marey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Kulisevsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,11,20]]},"reference":[{"key":"1114_CR1","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s11055-008-9085-3","volume":"38","author":"AN Boiko","year":"2008","unstructured":"Boiko AN, Batysheva TT, Minaeva NG et al (2008) Use of the new levodopa agent Stalevo (levodopa\/carbidopa\/entacapone) in the treatment of Parkinson\u2019s disease in out-patient clinical practice (the START-M open trial). Neurosci Behav Physiol 38:933\u2013936","journal-title":"Neurosci Behav Physiol"},{"key":"1114_CR2","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2147\/NDT.S1660","volume":"4","author":"DJ Brooks","year":"2008","unstructured":"Brooks DJ (2008) Optimizing levodopa therapy for Parkinson\u2019s disease with levodopa\/carbidopa\/entacapone: implications from a clinical and patient perspective. Neuropsychiatr Dis Treat 4:39\u201347","journal-title":"Neuropsychiatr Dis Treat"},{"key":"1114_CR3","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s00702-009-0344-4","volume":"117","author":"K Eggert","year":"2010","unstructured":"Eggert K, Skogar O, Amar K et al (2010) Direct switch from levodopa\/benserazide or levodopa\/carbidopa to levodopa\/carbidopa\/entacapone in Parkinson\u2019s disease patients with wearing-off: efficacy, safety and feasibility\u2014an open-label, 6-week study. J Neural Transm 117:333\u2013342","journal-title":"J Neural Transm"},{"issue":"Suppl 4","key":"1114_CR4","first-page":"IV37","volume":"252","author":"S Fahn","year":"2005","unstructured":"Fahn S (2005) Does levodopa slow or hasten the rate of progression of Parkinson\u2019s disease? J Neurol 252(Suppl 4):IV37\u2013IV42","journal-title":"J Neurol"},{"key":"1114_CR5","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1056\/NEJMoa033447","volume":"351","author":"S Fahn","year":"2004","unstructured":"Fahn S, Oakes D, Shoulson I et al (2004) Levodopa and the progression of Parkinson\u2019s disease. N Engl J Med 351:2498\u20132508","journal-title":"N Engl J Med"},{"key":"1114_CR6","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/mds.21878","volume":"24","author":"VS Fung","year":"2009","unstructured":"Fung VS, Herawati L, Wan Y (2009) Quality of life in early Parkinson\u2019s disease treated with levodopa\/carbidopa\/entacapone. Mov Disord 24:25\u201331","journal-title":"Mov Disord"},{"key":"1114_CR7","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1007\/s00702-004-0190-3","volume":"111","author":"A Gordin","year":"2004","unstructured":"Gordin A, Kaakkola S, Teravainen H (2004) Clinical advantages of COMT inhibition with entacapone\u2014a review. J Neural Transm 111:1343\u20131363","journal-title":"J Neural Transm"},{"key":"1114_CR8","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/mds.22343","volume":"24","author":"RA Hauser","year":"2009","unstructured":"Hauser RA, Panisset M, Abbruzzese G et al (2009) Double-blind trial of levodopa\/carbidopa\/entacapone versus levodopa\/carbidopa in early Parkinson\u2019s disease. Mov Disord 24:541\u2013550","journal-title":"Mov Disord"},{"key":"1114_CR9","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1046\/j.1468-1331.2003.00559.x","volume":"10","author":"JP Larsen","year":"2003","unstructured":"Larsen JP, Worm-Petersen J, Siden A et al (2003) The tolerability and efficacy of entacapone over 3\u00a0years in patients with Parkinson\u2019s disease. Eur J Neurol 10:137\u2013146","journal-title":"Eur J Neurol"},{"key":"1114_CR10","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1002\/mds.21944","volume":"23","author":"P Martinez-Martin","year":"2008","unstructured":"Martinez-Martin P, Tolosa E, Hernandez B et al (2008) Validation of the \u201cQUICK\u201d questionnaire\u2013a tool for diagnosis of \u201cwearing-off\u201d in patients with Parkinson\u2019s disease. Mov Disord 23:830\u2013836","journal-title":"Mov Disord"},{"key":"1114_CR11","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1212\/WNL.44.5.913","volume":"44","author":"JG Nutt","year":"1994","unstructured":"Nutt JG, Woodward WR, Beckner RM et al (1994) Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 44:913\u2013919","journal-title":"Neurology"},{"key":"1114_CR12","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/ana.410420511","volume":"42","author":"Parkinson Study Group","year":"1997","unstructured":"Parkinson Study Group (1997) Entacapone improves motor fluctuations in levodopa-treated Parkinson\u2019s disease patients. Parkinson Study Group. Ann Neurol 42:747\u2013755","journal-title":"Ann Neurol"},{"key":"1114_CR13","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1136\/jnnp.68.5.589","volume":"68","author":"P Piccini","year":"2000","unstructured":"Piccini P, Brooks DJ, Korpela K et al (2000) The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 68:589\u2013594","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1114_CR14","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1600-0404.2004.00363.x","volume":"111","author":"H Reichmann","year":"2005","unstructured":"Reichmann H, Boas J, Macmahon D et al (2005) Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations. Acta Neurol Scand 111:21\u201328","journal-title":"Acta Neurol Scand"},{"key":"1114_CR15","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1212\/WNL.51.5.1309","volume":"51","author":"UK Rinne","year":"1998","unstructured":"Rinne UK, Larsen JP, Siden A et al (1998) Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group. Neurology 51:1309\u20131314","journal-title":"Neurology"},{"key":"1114_CR16","doi-asserted-by":"crossref","first-page":"P25","DOI":"10.1007\/PL00007743","volume":"245","author":"HM Ruottinen","year":"1998","unstructured":"Ruottinen HM, Rinne UK (1998) COMT inhibition in the treatment of Parkinson\u2019s disease. J Neurol 245:P25\u2013P34","journal-title":"J Neurol"},{"key":"1114_CR17","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S1474-4422(05)70098-3","volume":"4","author":"A Schrag","year":"2005","unstructured":"Schrag A (2005) Entacapone in the treatment of Parkinson\u2019s disease. Lancet Neurol 4:366\u2013370","journal-title":"Lancet Neurol"},{"key":"1114_CR18","doi-asserted-by":"crossref","first-page":"483","DOI":"10.2147\/NDT.S5190","volume":"6","author":"P Solla","year":"2010","unstructured":"Solla P, Cannas A, Marrosu F et al (2010) Therapeutic interventions and adjustments in the management of Parkinson disease: role of combined carbidopa\/levodopa\/entacapone (Stalevo). Neuropsychiatr Dis Treat 6:483\u2013490","journal-title":"Neuropsychiatr Dis Treat"},{"key":"1114_CR19","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1517\/14656566.7.10.1399","volume":"7","author":"F Stocchi","year":"2006","unstructured":"Stocchi F (2006) The levodopa wearing-off phenomenon in Parkinson\u2019s disease: pharmacokinetic considerations. Expert Opin Pharmacother 7:1399\u20131407","journal-title":"Expert Opin Pharmacother"},{"key":"1114_CR20","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1159\/000300647","volume":"63","author":"F Stocchi","year":"2010","unstructured":"Stocchi F, Jenner P, Obeso JA (2010a) When do levodopa motor fluctuations first appear in Parkinson\u2019s disease? Eur Neurol 63:257\u2013266","journal-title":"Eur Neurol"},{"key":"1114_CR21","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/ana.22060","volume":"68","author":"F Stocchi","year":"2010","unstructured":"Stocchi F, Rascol O, Kieburtz K et al (2010b) Initiating levodopa\/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol 68:18\u201327","journal-title":"Ann Neurol"},{"key":"1114_CR22","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1001\/archneur.1969.00480160015001","volume":"21","author":"MD Yahr","year":"1969","unstructured":"Yahr MD, Duvoisin RC, Schear MJ et al (1969) Treatment of parkinsonism with levodopa. Arch Neurol 21:343\u2013354","journal-title":"Arch Neurol"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-013-1114-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00702-013-1114-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-013-1114-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T04:30:26Z","timestamp":1559104226000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00702-013-1114-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,20]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["1114"],"URL":"https:\/\/doi.org\/10.1007\/s00702-013-1114-x","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,20]]}}}